Hyperbaric Oxygen Therapy Center in Fairfield.


Lyme Disease and Hyperbaric Oxygen Therapy (HBOT).

Borrelia bacteria are microcephalic anaerobes, meaning that they don’t like a lot of oxygen. Under hyperbaric conditions, the concentration of oxygen can become great enough to kill Borrelia, especially in combination with antibiotic and/or herbal therapies.

Furthermore, since HBOT reduces inflammation in the brain and other tissues, it can bring healing and resolution to many of the inflammatory side effects of Lyme disease, such as brain fog and other neurological impairments.

While we normally breathe oxygen at a concentration of 21%, a patient in a hyperbaric oxygen chamber breathes 100% pure oxygen under pressure. This pressure allows oxygen to dissolve into the tissues such as lymph, and cerebrospinal fluids at concentrations not allowed under normal atmospheric conditions.

Lyme disease is included among the many conditions that may respond to HBOT.

In reading the study below by Dr. Fife, you will note that the purpose of his research was to determine if oxygen under pressure could kill the spirochete, Borrelia burgdorferi, which causes Lyme disease. The atmospheric levels of oxygen needed to kill the bacteria were determined and could safely be achieved in a hyperbaric chamber. Ninety-one subjects completed hyperbaric oxygen treatments. Of those treated, 84% showed significant improvement by a decrease or elimination of symptoms. 

Adam Breiner, ND, Fairfield, CT

Effects of Hyperbaric Oxygen Therapy On Lyme Disease

by William P. Fife, Ph. D.

29 January 1998

The purpose of this study was to determine if hyperbaric oxygen therapy affected Lyme disease caused by the spirochete, Borrelia burgdorferi.

The spirochete B. burgdorferi is a microaerophilic organism carried by the Deer tick (Ixodid) and transferred to humans and other mammals by its bite. Symptoms often begin by a bulls-eye rash and erythema migrans. Symptoms may include pain in joints and muscles, sore throat, fever, swollen glands, and mental ” fogginess”. If not diagnosed within the first one or two months, the disease may become a chronic infection. At that time it apparently becomes sequestered in fibroblasts and other cells which, in turn, appear to protect it against effective treatment by all known antibiotics so far tested. The disease is difficult to diagnose without serological findings and requires the skill of a highly qualified physician, experienced in treating this disease.


It was shown by Austin that the spirochete could not survive if transferred in the air to another host, but would survive if transferred in a gas mixture of 4% oxygen. This demonstrated that the spirochete could not survive in an oxygen partial pressure of 160-mm Hg (the partial pressure of oxygen in the air), but could survive in the partial pressure of 30-mm Hg (which is the partial pressure of 4% oxygen at 1 atmosphere, absolute (ground level pressure). Therefore, it seems clear that a lethal level of oxygen for the spirochete falls somewhere between 30 mm Hg, and 160 mm Hg.

It also is known that while the inspired partial pressure of oxygen is approximately 160 mm Hg, at the tissue level, the partial pressure of oxygen normally is approximately 30-35 mm Hg. Thus, it would not be expected that breathing air at ground level would cause any damage to the spirochete. However, if the patient were placed in a hyperbaric chamber and the pressure increased to 2. 36 atmospheres, absolute (ata), the total barometric pressure would be 1794 mm Hg. If the patient were then to breathe pure oxygen the inspired partial pressure of oxygen would be 1794 mm Hg. Inspired oxygen is diluted by carbon dioxide and water vapor in the alveoli, so that the arterial blood would be exposed to an oxygen partial pressure of approximately 1700-mm Hg, and the tissue oxygen would be between 200 and 300 mm Hg. This clearly would be above lethal oxygen levels for the spirochete since it is expected that oxygen normally would diffuse throughout all cells of the body.

This partial pressure of oxygen can be safely achieved in a hyperbaric chamber, and the patients can tolerate this level for 90 minutes or longer quite successfully.


This study was approved by the University Institutional Review Board.

Subjects were selected from those referred by clinical physicians who were experienced in the treatment of Lyme disease. All subjects presented with a positive diagnosis of this disease according to the CDC criteria, including a positive Western blot serology of the proper bands. All had failed intravenous antibiotics, and many were continuing to deteriorate even though still on various antibiotics.

Subjects were given a briefing on the use of the hyperbaric chamber, including the risks, and signed a waiver and release in accordance with the Belmont Report. They were placed in the multiplace chamber and compressed to 2.36 ata, whereupon a plastic helmet was placed over the head and pure oxygen was administered. The oxygen flow pattern was such that the subject inspired 100% oxygen with each breath. Subjects were able to communicate with the attendant in the chamber as well as with each other.

Treatment duration was 60 minutes on oxygen, and in most instances, the treatments were administered bid for 5 days followed by a two-day rest. Several different series were tried, ranging from 10 treatments to 30 treatments. One subject received 145 treatments over the course of 3 months.


Ninety-one subjects completed a total of 1,995 hyperbaric oxygen treatments, although nine were eliminated later due to the presence of another medical problem not apparent during their treatments. These other medical problems were such things as babesiosis, ehrlichiosis, hepatitis C, and previously unidentified neurological problems. Two subjects were eliminated due to the development of septicemia from IV catheters, and one because of recent breast cancer, although all three of them later showed an improvement of Lyme symptoms with hyperbaric oxygen administration.

The subject evaluation was carried out by an abbreviated questionnaire taken from a standard questionnaire used by several Lyme specialists as part of their evaluation. This questionnaire was designed so that zero reflected no symptoms, while ten reflected severe symptoms.

Although additional statistical evaluation still is being carried out, it appears that approximately 84.8% of those treated showed significant improvement by a decrease or elimination of symptoms. Only 12 subjects (13.1%) claimed no apparent benefit.

Before treatment, the subjects had an average score of 114.12 (of a possible 270), and after treatment, they averaged 49.27. This reduction of 64.85 points was statistically significant in a paired t-test (p=0.000). The variability of the scores from patient-to-patient declined as well after the treatment series. The standard deviation of the scores was 56.00 before and 44.14 after treatment. The p-value of this reduction is 0.057 in Fisher’s F-test. Further, 58% of the respondents had a score reduction of 41.86 points or more.

All except one of the 91 subjects developed severe Jarisch-Herxheimer* reaction, usually appearing within the first 5 days of the beginning of hyperbaric oxygen treatment. In most cases, the Jarisch-Herxheimer reaction continued throughout the series of treatments, and in many instances continued for up to a month after the treatments were finished. Most subjects then began to show major improvement that in some instances has continued for 8 months.

*Herxheimer’s reaction is caused by toxins released by the large number of dead spirochetes eliminated during the initial part of treatment. This means that symptoms will worsen temporarily. While this is a positive indication the treatment is working, at Whole-Body Medicine, we try and take measures to reduce the severity of the Herxheimer’s reaction.

If you are suffering from Lyme Disease and wish to consider Hyperbaric Oxygen Therapy or one of our other Innovative Treatments for Lyme Disease please call 203-371-8258 to schedule a consultation.

Call Now Button